Why is Brawn Biotech falling/rising?

As of 18-Aug, Brawn Biotech Ltd's stock price is currently at 18.00, reflecting a decrease of 0.01, or 0.06%. The stock has underperformed its sector today by 1.91% and has experienced a trend reversal, falling after two consecutive days of gains. Over the past week, the stock has shown a positive return of 2.86%, but it has declined by 3.23% over the past month and has a year-to-date drop of 15.53%. The company's long-term fundamentals are weak, with an average Return on Equity (ROE) of 0% and significant declines in net sales and operating profit over the last five years. Additionally, the stock is considered risky due to a negative EBITDA and a poor EBIT to Interest ratio, which may contribute to its recent price movement.
In the broader market context, while the Sensex has gained 0.83% over the past week, Brawn Biotech's performance has lagged behind, indicating a relative weakness in comparison to the benchmark. The stock's liquidity is adequate, with a delivery volume that has increased significantly, suggesting some investor interest; however, the overall negative sentiment driven by weak financial performance and growth prospects continues to weigh on the stock's price.